- Page 1: Towa r d s c l i n i c a l Tc r g e
- Page 4 and 5: Studies described in this thesis we
- Page 6 and 7: PROMOTIECOMMISSIE Promotor: Prof.dr
- Page 11 and 12: 1.1 IMMunE ThERaPy fOR ThE TREaTMEn
- Page 13 and 14: 1. Isolation and activation of peri
- Page 15 and 16: General Introduction synovial carci
- Page 17 and 18: Table 3. Challenges of TCR gene the
- Page 19 and 20: General Introduction Table 4. Stren
- Page 21 and 22: 1.3.2 Environmentally induced tumor
- Page 23 and 24: General Introduction adoptive T cel
- Page 25 and 26: General Introduction would require
- Page 27 and 28: General Introduction different plat
- Page 29 and 30: REfEREnCES General Introduction 1.
- Page 31 and 32: General Introduction metastatic syn
- Page 33 and 34: General Introduction 51. Schambach
- Page 35 and 36: General Introduction 80. Leach DR,
- Page 37 and 38: General Introduction 112. Umansky V
- Page 39 and 40: General Introduction 142. Hanson HL
- Page 41: General Introduction 172. Liu W, Ch
- Page 44 and 45: Chapter 2 aBSTRaCT Importance of th
- Page 46 and 47: Chapter 2 receptors, CARs) to treat
- Page 48 and 49: Chapter 2 Table 2. advantages of Ma
- Page 50 and 51: Chapter 2 within a vector is of imp
- Page 52 and 53: Chapter 2 expression and pMHC multi
- Page 54 and 55: Chapter 2 potential in eradicating
- Page 56 and 57: Chapter 2 differentiation state and
- Page 58 and 59:
Chapter 2 recognize such a self-ant
- Page 60 and 61:
Chapter 2 Table 3. Strategies to im
- Page 62 and 63:
Chapter 2 60 3. Lymphodepletion Iso
- Page 64 and 65:
Chapter 2 CC, Rudy SF, VanWaes C, D
- Page 66 and 67:
Chapter 2 42. Schultz ES, Schuler-T
- Page 68 and 69:
Chapter 2 73. Sadelain M, Brentjens
- Page 70 and 71:
Chapter 2 105. Moroz A, Eppolito C,
- Page 72 and 73:
Chapter 2 134. Willemsen RA, Sebest
- Page 75 and 76:
Chapter 3 T cell receptor gene ther
- Page 77 and 78:
InTRODuCTIOn TCR-engineered T cells
- Page 79 and 80:
OV-CAR3 (MUC-CD) cells OC SCID Beig
- Page 81 and 82:
TCR-engineered T cells in SCID and
- Page 83 and 84:
AT models TCR-engineered T cells in
- Page 85 and 86:
A tumor volume (mm 3 ) 800 700 600
- Page 87 and 88:
TCR-engineered T cells in SCID and
- Page 89 and 90:
TCR-engineered T cells in SCID and
- Page 91 and 92:
DISCuSSIOn TCR-engineered T cells i
- Page 93 and 94:
TCR-engineered T cells in SCID and
- Page 95 and 96:
REfEREnCES TCR-engineered T cells i
- Page 97 and 98:
TCR-engineered T cells in SCID and
- Page 99 and 100:
TCR-engineered T cells in SCID and
- Page 101 and 102:
TCR-engineered T cells in SCID and
- Page 103:
REfEREnCES: TCR-engineered T cells
- Page 106 and 107:
Chapter 4 aBSTRaCT Clinical therapy
- Page 108 and 109:
Chapter 4 transferred and the occur
- Page 110 and 111:
Chapter 4 bind gp100/A2 pMHC, which
- Page 112 and 113:
Chapter 4 RESulTS TCR T cells preve
- Page 114 and 115:
Chapter 4 figure 1. Treatment with
- Page 116 and 117:
Chapter 4 114 day Bu 0 ….. 10 tum
- Page 118 and 119:
Chapter 4 116 B genomic DNA (arbitr
- Page 120 and 121:
Chapter 4 cells in the viable gate
- Page 122 and 123:
Chapter 4 that relapsed tumors func
- Page 124 and 125:
Chapter 4 are in line with previous
- Page 126 and 127:
Chapter 4 124 tumor growth Treatmen
- Page 128 and 129:
Chapter 4 11. Mackensen A, Meidenba
- Page 130 and 131:
Chapter 4 42. Zou W (2005) Immunosu
- Page 132 and 133:
Chapter 4 Assessment of promoter me
- Page 134 and 135:
Chapter 4 132 lymphocytes (number /
- Page 136 and 137:
Chapter 4 HLA-A2 transgenic mice be
- Page 138 and 139:
Chapter 5 aBSTRaCT Adoptive therapy
- Page 140 and 141:
Chapter 5 in up to 50% of non-small
- Page 142 and 143:
Chapter 5 140 MC2/A2 peptide MHC (p
- Page 144 and 145:
Chapter 5 duction procedure was des
- Page 146 and 147:
Chapter 5 figure 2. Primary human T
- Page 148 and 149:
Chapter 5 figure 4. Surface express
- Page 150 and 151:
Chapter 5 figure 7. Ma3/DP4 TCR CD4
- Page 152 and 153:
Chapter 5 extent of lysis, a typica
- Page 154 and 155:
Chapter 5 may provide a preclinical
- Page 156 and 157:
Chapter 5 12. Parkhurst MR, Yang JC
- Page 158 and 159:
Chapter 5 40. Carrasco J, Van Pel A
- Page 160 and 161:
Chapter 5 68. Kuball J, Schmitz FW,
- Page 162 and 163:
Chapter 5 melanoma cells; MC2 pos /
- Page 164 and 165:
Chapter 6 Currently, TCR gene thera
- Page 166 and 167:
Chapter 6 murine T cells with solub
- Page 168 and 169:
Chapter 6 6.2.1 Major findings of t
- Page 170 and 171:
Chapter 6 mouse antibody sequences
- Page 172 and 173:
Chapter 6 (IDO) and arginase that d
- Page 174 and 175:
Chapter 6 enhance T cell accumulati
- Page 176 and 177:
Chapter 6 MAGE surface expression l
- Page 178 and 179:
Chapter 6 1. Isolation and activati
- Page 180 and 181:
Chapter 6 REfEREnCES 1. Powell DJ,
- Page 182 and 183:
Chapter 6 F, Bordignon C & Bonini C
- Page 184 and 185:
Chapter 6 58. Spiotto MT, Rowley DA
- Page 186 and 187:
Chapter 6 CD8+ T cells expressing i
- Page 188 and 189:
Chapter 6 118. Kantarjian HM, O’B
- Page 191 and 192:
SuMMaRy Summary To date, adoptive T
- Page 193 and 194:
Summary 20% of mice durable remissi
- Page 195 and 196:
SaMEnVaTTIng Samenvatting Momenteel
- Page 197 and 198:
Samenvatting experimenten laten wij
- Page 199:
Curriculum Vitae List of publicatio
- Page 203:
lIST Of PuBlICaTIOnS List of public
- Page 206 and 207:
PhD portfolio 1.4b Poster presentat
- Page 208:
Samenvatting In het bijzonder wil i